Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



After Hours: Dendreon's Shares Crushed Again

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Dendreon (Nasdaq: DNDN  ) has done it again.

Its third quarter earnings report is all about prostate cancer vaccine Provenge, and once again the company has managed to disappoint investors. Shares are getting pounded in after-market trading, down more than 20%.

The company managed to exceed revenue expectations but whiffed badly on earnings. It also called for "modest" growth in Provenge sales in the near term.

The most concerning thing for investors was the guidance. Dendreon doesn't even have the luxury of living in a "what have you done for me lately" world; it needs to show what it's doing to create value for investors tomorrow. These two excerpts from the conference call from management discussing "modest" fourth-quarter sales expectations stood out as exceptionally problematic:

  • "Looking ahead, we see our November bookings slightly below our October bookings."
  • "I think the almost 30% growth that we saw in the third quarter would probably exceed what we would classify as modest growth."

Dendreon expects sales growth to shrink! Possibly dramatically. Sure, seasonality is a factor (who wants to get treatment during the holidays?), but to blame the continued stumbling of Provenge's product launch on Thanksgiving and Christmas reeks of deflection.

Going it alone is all the rage, but for every Vertex Pharmaceuticals (Nasdaq: VRTX  ) , where its Hepatitis C drug Incivek is beating the pants off Merck (NYSE: MRK  ) and its established sales force, you have an Acorda Therapeutics (Nasdaq: ACOR  ) and AVANIR Pharmaceuticals (Nasdaq: AVNR  ) , where sales of their new drugs have been disappointing.

It's not for a lack of promise, but going it alone may have been a big strategic error for the company and shareholder value.

Add Dendreon to My Watchlist to stay tuned to the Fool's continuing coverage of the company. Check out tomorrow, when our health-care expert Brian Orelli will offer the post-mortem of tonight's earnings announcement and a look at what lies ahead for Dendreon.

Fool contributor David Williamson owns shares of Dendreon, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 03, 2011, at 1:19 AM, sinnersun wrote:

    Great stuff. I agree abt the going it alone theory. Now VRTX is toast as VRUS's drug is superior on all counts imo. There's a good piece on Acorda at Psychology of the Call blog by the way:


  • Report this Comment On November 03, 2011, at 2:24 AM, Yourdeadmeat69 wrote:

    Nothing wrong with modest growth, the problem is always waiting for the govt to pay (Medicare/Medicaid). Biotech is always dicey, but these guys have the better mousetrap.

    Instant gratification, no, better mousetrap? nope.

    Shares are cheap, may get cheaper, forward looking is good, not great, but at these levels? Haircut is a buying op imho.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1582767, ~/Articles/ArticleHandler.aspx, 10/24/2016 3:28:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ACOR $20.10 Down -0.10 -0.50%
Acorda Therapeutic… CAPS Rating: ****
AVNR.DL $0.00 Down +0.00 +0.00%
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
VRTX $80.76 Down -2.16 -2.60%
Vertex Pharmaceuti… CAPS Rating: ****